Regions Financial Corp Biomarin Pharmaceutical Inc Transaction History

Regions Financial Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 15, 2020	SELL	$71.87 - $131.03 $142,661 - $260,094	-1,985 Closed	0 $0
Q2 2020 Jul 27, 2020	SELL	$79.55 - $124.22 $34,126 - $53,290	-429 Reduced 17.77%	1,985 $245,000
Q1 2020 Apr 29, 2020	SELL	$71.37 - $96.85 $13,274 - $18,014	-186 Reduced 7.15%	2,414 $204,000
Q4 2019 Feb 03, 2020	BUY	$64.27 - $86.37 $167,102 - $224,562	2,600 New	2,600 $220,000
Q3 2019 Oct 24, 2019	SELL	$67.4 - $85.11 $193,438 - $244,265	-2,870 Closed	0 $0
Q2 2019 Jul 19, 2019	SELL	$80.35 - $93.9 $11,007 - $12,864	-137 Reduced 4.56%	2,870 $246,000
Q1 2019 Apr 19, 2019	BUY	$84.2 - $98.62 $38,142 - $44,674	453 Added 17.74%	3,007 $267,000
Q4 2018 Jan 28, 2019	SELL	$80.14 - $106.07 $8,655 - $11,455	-108 Reduced 4.06%	2,554 $217,000
Q3 2018 Oct 22, 2018	BUY	$93.92 - $105.72 $30,430 - $34,253	324 Added 13.86%	2,662 $258,000
Q2 2018 Jul 26, 2018	BUY	$76.01 - $99.03 $3,116 - $4,060	41 Added 1.78%	2,338 $221,000
Q4 2017 Jan 18, 2018	SELL	$80.76 - $95.13 $2,180 - $2,568	-27 Reduced 1.16%	2,297 $205,000
Q3 2017 Oct 23, 2017	BUY	$80.6 - $94.95 $187,314 - $220,663	2,324	2,324 $216,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Regions Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Regions Financial Corp with notifications on news.